Wall Street analyst estimates for Adlai Nortye Ltd. (ANL): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-03-03 | $-0.15 | ||
| 2026-08-14 | $-0.04 | $-0.04 | +7.9% |
| 2026-04-29 | $-0.18 | ||
| 2026-04-10 | $-0.81 | $-0.18 | -350.0% |
| 2025-12-29 | $-0.18 | $-0.18 | +0.0% |
| 2025-08-07 | $-0.18 | $-0.18 | +0.0% |
| 2025-04-30 | $-0.22 | $-0.53 | +58.5% |
| 2025-02-26 | $-0.22 | $-0.53 | +58.5% |
Valuation Ratios
| Price / Book | 1.17 |
| EV / EBITDA | -32.67 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $45.7M | 0 | 0 | 0 | $5.0M |
| Cost of Revenue | $1.5M | $1.5M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$1.5M | -$1.5M | $45.7M | 0 | 0 | 0 | $5.0M |
| Research & Development | $13.3M | $19.0M | $42.1M | $54.5M | $58.2M | $44.9M | $32.8M |
| Selling, General & Admin | $4.3M | $5.6M | $12.4M | $12.4M | $14.8M | $9.4M | $7.8M |
| Operating Expenses | $17.6M | $24.6M | $54.4M | $67.3M | $72.6M | $52.9M | $40.7M |
| Operating Income | -$19.1M | -$26.1M | -$8.6M | -$67.3M | -$72.6M | -$52.9M | -$35.7M |
| EBITDA | -$15.9M | -$60.1M | -$53.5M | -$56.3M | -$106.2M | -$48.1M | -$32.6M |
| Interest Expense | $466145 | $1.7M | $1.3M | $433000 | $791000 | $1.9M | $1.5M |
| Pre-tax Income | -$17.8M | -$63.4M | -$56.7M | -$58.8M | -$109.2M | -$51.9M | -$35.5M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$17.8M | -$63.4M | -$56.7M | -$58.8M | -$109.2M | -$51.9M | -$35.5M |
| EPS | $-2.10 | $-7.62 | $-4.62 | $-4.77 | $-15.42 | $-4.89 | $-3.33 |
| EPS (Diluted) | $-2.10 | $-7.62 | $-4.62 | $-4.77 | $-15.42 | $-4.89 | $-3.33 |
| Shares Outstanding (Diluted) | $8.5M | $8.5M | $12.3M | $12.3M | $6.8M | $10.6M | $10.7M |
Price
| Price | $15.52 |
| Market Cap | $824M |
| Exchange | NASDAQ |
| Country | SG |
Related companies: ADAP · ADTX · AIMD · APLM · BLRX · GOVX · ICU
Explore sector: Healthcare · Biotechnology
More sections of ANL: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks